Document is current
Any future updates will be listed below
-
Authors
Singh, Ashutosh
Cheng, Donghang
Haltom, Amanda R.
Yang, Yanwen
Dobson, Tara
Hatcher, Rashieda
Rajaram, Veena
Gopalakrishnan, Vidya https://orcid.org/0000-0002-4448-4698
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (5R01NS079715)
Addi's Faith Foundation.
- License Information
-
More Information
Article History
Received: 20 January 2025
Revised: 5 November 2025
Accepted: 21 November 2025
First Online: 18 December 2025
Competing interests
: The authors declare no competing interests.
: All methods in this study were performed in accordance with relevant guidelines and regulations as indicated below. Histopathological analyses of SHH-MB tumor sections were performed by Dr. Veena Rajaram (collaborating neuropathologist) at UT Southwestern Medical Center. MB samples were collected under the auspices of the Institutional Review Board (IRB)-approved protocol STU 022011-081 from patients enrolled in clinical trials following receipt of informed consent. Samples were de-identified prior to use for immunohistochemical analyses. For experiments involving mice, housing, maintenance, and research methods were done in compliance with a protocol approved by the UT MD Anderson Cancer Center’s Institutional Animal Care and Use Committee (IACUC)-approved protocol #00001080 guidelines. Our study is reported in accordance with ARRIVE guidelines ( ).
